Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial
Top Cited Papers
Open Access
- 26 August 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (37) , 3789-3800
Abstract
Evidence is lacking that correcting iron deficiency (ID) has clinically important benefits for patients with heart failure with preserved ejection fraction (HFpEF). FAIR-HFpEF was a multicentre, randomized, double-blind trial designed to compare intravenous ferric carboxymaltose (FCM) with placebo (saline) in 200 patients with symptomatic HFpEF and ID (serum ferritin < 100 ng/mL or ferritin 100–299 ng/mL with transferrin saturation < 20%). The primary endpoint was change in 6-min walking test distance (6MWTD) from baseline to week 24. Secondary endpoints included changes in New York Heart Association class, patient global assessment, and health-related quality of life (QoL). The trial was stopped because of slow recruitment after 39 patients had been included (median age 80 years, 62% women). The change in 6MWTD from baseline to week 24 was greater for those assigned to FCM compared to placebo [least square mean difference 49 m, 95% confidence interval (CI) 5–93; P = .029]. Changes in secondary endpoints were not significantly different between groups. The total number of adverse events (76 vs. 114) and serious adverse events (5 vs. 19; rate ratio 0.27, 95% CI 0.07–0.96; P = .043) was lower with FCM than placebo. In patients with HFpEF and markers of ID, intravenous FCM improved 6MWTD and was associated with fewer serious adverse events. However, the trial lacked sufficient power to identify or refute effects on symptoms or QoL. The potential benefits of intravenous iron in HFpEF with ID should be investigated further in a larger cohort. Main design features and outcomes of the FAIR-HFpEF trial. AF, atrial fibrillation; BNP, B-type natriuretic peptide; HF, heart failure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; TSAT, transferrin saturation.Keywords
Funding Information
- Vifor Pharma
This publication has 39 references indexed in Scilit:
- Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatmentClinical Research in Cardiology, 2024
- Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of HypertensionEuropean Journal of Heart Failure, 2023
- Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron DeficiencyJournal of Cardiac Failure, 2022
- Muscle Mass, Muscle Strength, and Functional Capacity in Patients with Heart Failure of Chagas Disease and Other AetiologiesESC Heart Failure, 2020
- Muscle wasting as an independent predictor of survival in patients with chronic heart failureJournal of Cachexia, Sarcopenia and Muscle, 2020
- Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trialsEuropean Journal of Heart Failure, 2020
- Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection FractionJAMA, 2016
- Minimal important difference for 6-minute walk test distances among patients with chronic heart failureInternational Journal of Cardiology, 2014
- Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial)International Journal of Cardiology, 2011
- Effect of Long-Acting Testosterone Treatment on Functional Exercise Capacity, Skeletal Muscle Performance, Insulin Resistance, and Baroreflex Sensitivity in Elderly Patients With Chronic Heart FailureJACC, 2009